InsiderTrades

Form 4 for CTSO Cytosorbents Corp

Accepted 2021-09-02 00:00:00 ET · period of report 2021-08-31 · accession 0001104659-21-112499 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-09-02 2021-08-31 CTSO Kraus Al Dir M - OptEx $4.13 +4,000 129.0K +3% +$16.5K
D 2021-09-02 2021-08-31 CTSO Kraus Al Dir S - Sale+OE $9.40 -4,000 125.0K -3% -$37.6K
D 2021-09-02 2021-08-31 CTSO Kraus Al Dir M - OptEx $0.00 -4,000 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-08-31 M A 4,000 $4.13 129,046 D — —
2 Common Common Stock 2021-08-31 S D 4,000 $9.40 125,046 D — — (F1) Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. (F2) Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.
3 Derivative Stock Option (right to buy) 2021-08-31 M D 4,000 $0.00 0 D $4.13 · 2012-01-18 to 2022-01-18 4,000 Common Stock